Related Experiment Videos
Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study
Salvatore D'Angelo1, Giovanna Cuomo, Carmen Paone
1Rheumatology Unit, Department of Clinical and Experimental Medicine, Second University of Naples, Edificio 3, Via Pansini 5, 80131 Naples, Italy.
Clinical Rheumatology
|December 17, 2003
Summary
Low-dose intravenous cyclophosphamide (CYC) shows promise for treating systemic sclerosis (SSc). This treatment was well-tolerated in a small trial, with minimal side effects observed in SSc patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- High-dose cyclophosphamide (CYC) regimens for systemic sclerosis (SSc) are linked to significant adverse effects.
- The need for safer treatment options for SSc is critical.
Purpose of the Study:
- To evaluate the safety and tolerability of low-dose intravenous CYC in patients with SSc.
- To identify and monitor potential side effects associated with this reduced-dose regimen.
Main Methods:
- A trial involving eight SSc patients receiving intravenous CYC (500 mg pulses) over a 6-month period.
- Systematic monitoring for adverse events, including specific assessments for amenorrhea, leukopenia, ovarian failure, cystitis, hematuria, and liver toxicity.
Main Results:
- The low-dose intravenous CYC therapy was generally well-tolerated by all participants.
- No patients discontinued treatment due to adverse events. Serious side effects like leukopenia, ovarian failure, and organ toxicity were not observed.
- The most frequent adverse events reported were mild, self-limiting nausea and weakness.
Conclusions:
- Low-dose intravenous CYC appears to be a relatively safe short-term treatment option for systemic sclerosis.
- Further research is necessary to confirm the efficacy and long-term safety profile of this therapeutic approach.